The estimated Net Worth of Christina Rossi is at least $10.4 Milhão dollars as of 7 March 2024. Ms. Rossi owns over 6,070 units of Blueprint Medicines Corp stock worth over $5,566,327 and over the last 6 years she sold BPMC stock worth over $1,061,260. In addition, she makes $3,745,260 as Chief Commercial Officer at Blueprint Medicines Corp.
Christina has made over 9 trades of the Blueprint Medicines Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 6,070 units of BPMC stock worth $550,488 on 7 March 2024.
The largest trade she's ever made was selling 6,070 units of Blueprint Medicines Corp stock on 7 March 2024 worth over $550,488. On average, Christina trades about 905 units every 93 days since 2018. As of 7 March 2024 she still owns at least 64,306 units of Blueprint Medicines Corp stock.
You can see the complete history of Ms. Rossi stock trades at the bottom of the page.
Christina Rossi serves as Chief Commercial Officer of the Company. She has served as our chief commercial officer since October 2018. Prior to joining us, from January 2015 to October 2018, Ms. Rossi served as the Multiple Sclerosis Business Unit Head, North America, at Sanofi Genzyme. In this role, she was responsible for all aspects of the financial performance of Sanofi Genzyme’s multiple sclerosis franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Ms. Rossi served as Vice President, Multiple Sclerosis Sales at Sanofi Genzyme form May 2014 to December 2015 and Vice President, Multiple Sclerosis Patient and Provider Services at Sanofi Genzyme from June 2012 to May 2014. Prior to joining Sanofi Genzyme, Ms. Rossi served in various roles at Biogen, Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, Ms. Rossi consulted in the healthcare practice at the Boston Consulting Group. Ms. Rossi holds a B.S. in biology, cum laude, from Duke University and an M.B.A. from Harvard Business School.
As the Chief Commercial Officer of Blueprint Medicines Corp, the total compensation of Christina Rossi at Blueprint Medicines Corp is $3,745,260. There are 1 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
Christina Rossi is 44, she's been the Chief Commercial Officer of Blueprint Medicines Corp since 2018. There are 28 older and 1 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
Christina's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr, eLonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: